Conditions: Type 2 Diabetes Mellitus
Keywords: DPP-IV inhibitor
Allocation: NON_RANDOMIZED | Intervention model: PARALLEL
Enrollment: 240
Healthy volunteers: no

Brief summary:
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) as monotherapy or in combination with Sulfonylurea (glimepiride) in Japanese patients with type 2 Diabetes for 52 weeks administration.

Detailed description:

Arms:
arm 1: Teneligliptin for 52 weeks arm 2: Teneligliptin for 52 weeks in combination with sulfonylurea

Interventions: intervention 1: Teneligliptin intervention 2: Teneligliptin + Sulfonylurea
Intervention descriptions: intervention 1: Teneligliptin for 52 weeks intervention 2: Teneligliptin for 52 weeks in combination with sulfonylurea

Protocol document: